Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.35 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21743928 | 0.80 | ALDH1A1 (0.46) | BTN3A1ALDH1A1MAPTCA12CA9 | |
| SCHEMBL23077322 | 0.77 | CASP3 (0.40) | ALDH1A1CASP3MAPTRECQLHPGD | |
| SCHEMBL23077326 | 0.77 | CASP3 (0.40) | ALDH1A1CASP3MAPTRECQLHPGD | |
| SCHEMBL27949389 | 0.77 | ALDH1A1 (0.44) | ALDH1A1CASP3CA12CA9HSD17B10 | |
| SCHEMBL21744324 | 0.76 | ALDH1A1 (0.44) | ALDH1A1MAPTCA12CA9 | |
| SCHEMBL11292227 | 0.76 | ALDH1A1 (0.50) | ALDH1A1CASP3MAPTRECQLCA12 | |
| SCHEMBL21744525 | 0.74 | ALDH1A1 (0.50) | ALDH1A1CASP3MAPTCA12CA9 | |
| SCHEMBL1973155 | 0.74 | ALDH1A1 (0.50) | ALDH1A1CASP3MAPTCA12CA9 | |
| SCHEMBL1973157 | 0.74 | ALDH1A1 (0.50) | ALDH1A1CASP3MAPTCA12CA9 | |
| SCHEMBL12903756 | 0.74 | HPGD (0.51) | ALDH1A1CASP3MAPTHPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2023-04-13 | — | — | US | disclosed |
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | EMORY UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | BTN3A1 2858/4885ALDH1A1 1760/4885CASP3 2722/4885 |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | BTN3A1 2858/4885ALDH1A1 1760/4885CASP3 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.